Pyxis Oncology (NASDAQ:PYXS) Price Target Raised to $8.00

Pyxis Oncology (NASDAQ:PYXS) had its price objective boosted by stock analysts at HC Wainwright from $7.00 to $8.00 in a research note issued to investors on Thursday, MarketBeat reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 136.69% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on PYXS. Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Wells Fargo & Company increased their target price on shares of Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a research report on Wednesday. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Pyxis Oncology in a research note on Thursday. Weiss Ratings cut shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Finally, Leerink Partners cut their price objective on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, July 2nd. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.75.

Pyxis Oncology Trading Down 13.1%

Shares of NASDAQ PYXS opened at $3.38 on Thursday. The stock has a fifty day simple moving average of $3.01 and a two-hundred day simple moving average of $2.22. Pyxis Oncology has a 1-year low of $1.03 and a 1-year high of $5.55. The firm has a market cap of $281.93 million, a price-to-earnings ratio of -2.40 and a beta of 1.34.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Analysts forecast that Pyxis Oncology will post -1.21 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PYXS. Atle Fund Management AB bought a new position in shares of Pyxis Oncology in the fourth quarter worth $710,000. 683 Capital Management LLC boosted its stake in Pyxis Oncology by 69.9% during the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after buying an additional 366,910 shares during the period. OMERS ADMINISTRATION Corp bought a new stake in Pyxis Oncology during the fourth quarter valued at $77,000. Barclays PLC grew its position in Pyxis Oncology by 1,939.3% during the fourth quarter. Barclays PLC now owns 60,385 shares of the company’s stock worth $69,000 after buying an additional 57,424 shares in the last quarter. Finally, HRT Financial LP grew its position in Pyxis Oncology by 157.5% during the fourth quarter. HRT Financial LP now owns 39,649 shares of the company’s stock worth $45,000 after buying an additional 24,251 shares in the last quarter. Hedge funds and other institutional investors own 39.07% of the company’s stock.

Trending Headlines about Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: MICVO produced encouraging Phase 1 results. In patients with second-line-and-beyond recurrent/metastatic head and neck squamous cell carcinoma, micvotabart pelidotin (MICVO) generated a 36% confirmed objective response rate, a 94% disease-control rate, median progression-free survival of 6.2 months and a 79% probability of overall survival at 12 months. Responses were observed across HPV status and prior-treatment groups. Pyxis Oncology Announces Positive Updated MICVO Data
• Positive Sentiment: The company plans to advance MICVO into pivotal testing. Pyxis said the data support a Phase 3 Headliner trial in this cancer setting, expected to begin in mid-2027. It also reported no new safety signals, while dose capping reduced the frequency and severity of adverse events among higher-weight patients. Pyxis Oncology Reports 36% Response Rate
• Positive Sentiment: Analyst support remains favorable. Wells Fargo raised its PYXS price target to $19 from $12 and maintained an “overweight” rating. The company also received a broader “Moderate Buy” consensus rating, although analyst targets remain highly speculative for a clinical-stage biotechnology company. Wells Fargo Raises Pyxis Oncology Price Target
• Neutral Sentiment: Management changes provide continuity but add another transition point. Thomas Civik, previously interim CEO, was appointed CEO and chairman, while co-founder John Flavin became lead independent director. Civik’s experience includes leadership roles at Five Prime Therapeutics and other acquired biotechnology companies. Pyxis Oncology Appoints Thomas Civik
• Negative Sentiment: The market reaction highlights lingering development risk. PYXS declined after the update even though the headline results were positive, likely because the evidence remains Phase 1, the study is early and potentially limited in size, and the Phase 3 program is not expected to start until 2027. Investors will also await durability data and results from the MICVO-pembrolizumab combination study expected in the fourth quarter of 2026. Pyxis Oncology Shares React to MICVO Results

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.